Swetha Bindu Velaga, None;
Muneeswar Gupta Nittala, None;
Tyler Brown, None;
Zhihong Hu, None;
Charles Wykoff, Adverum Biotechnologies , Inc (F), Aerpio Therapeutics (F), Alcon Laboratories (F), Alcon Laboratories, Inc (C), Alimera Sciences, Inc (C), Allergan, Inc (C), Allergan, Inc (F), Apellis Pharmaceutical (F), Apellis Pharmaceutical; Bayer AG (C), Clearside Biomedical, Inc (C), Clearside Biomedical, Inc (F), D.O.R.C. International (C), Genentech, Inc (C), Genentech, Inc (F), Novartis International AG (C), Novartis International AG (F), ONL Therapeutics, Inc. (C), Ophthotech Corporation (F), Regeneron Pharmaceuticals, Inc (C), Regeneron Pharmaceuticals, Inc (F), Regenxbio Inc (C), Roche (C), Roche Holding AG (F), Santen Inc (C), Santen Inc (F);
Michael Ip, Allergan (C), Astellas Institute for Regenerative Medicine (C), Boehringer Ingelheim (C), Genentech (C), Omeros (C), Quark (C), Thrombogenics (C);
Srinivas Sadda, Allergan (C), Amgen (C), Carl Zeiss Meditec (F), Centervue (C), Centervue (F), Genentech/Roche (C), Heidelberg (C), Nidek (F), Novartis (C), Optos (C), Optos (F), Oxurion (C), Topcon (F)